Hernandez Tejada, Fiorela N.
Zamudio, Alejandro
Marques-Piubelli, Mario L.
Cuglievan, Branko
Harrison, Douglas http://orcid.org/0000-0002-6776-4852
Article History
Accepted: 5 November 2020
First Online: 16 November 2020
Compliance with Ethical Standards
:
: Fiorela N. Hernandez Tejada, Alejandro Zamudio, Mario L. Marques-Piubelli, and Branko Cuglievan declare no conflict of interest. Douglas Harrison receives 2% salary support from Salarius Pharmaceuticals, which supports one of the clinical trials for Ewing sarcoma cited in this article (phase I trial of LSD-1 inhibitor, seclidemstadt).
: This article does not contain any studies with human or animal subjects performed by the authors.